Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AAC...
April 03 2019 - 8:02AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today reported data on
JTX-8064, its first tumor-associated macrophage program, at the
2019 American Association for Cancer Research (AACR) Annual Meeting
in Atlanta, GA. The poster presentation includes preclinical data
demonstrating the immunotherapeutic properties of JTX-8064 to
reprogram immune-suppressive macrophages within the tumor
microenvironment.
“Today, we presented the characterization of JTX-8064 and the
preclinical data for this novel product candidate, demonstrating
its potential in re-programming tumor-associated macrophages within
the tumor microenvironment to enhance anti-tumor immunity. We
believe that LILRB2 functions as an immune checkpoint for
macrophages and have demonstrated differentiation from other
macrophage-directed approaches,” said Elizabeth Trehu, M.D., chief
medical officer of Jounce Therapeutics. “New insights from our
Translational Science Platform continue to inform JTX-8064
development and we expect to file an Investigational New Drug
application and initiate a Phase 1 clinical trial later this
year.”
In a poster titled “Preclinical evaluation of JTX-8064,
an anti-LILRB2 antagonist antibody, for reprogramming
tumor-associated macrophages,” Jounce researchers describe
the preclinical evaluation of JTX-8064 including:
- JTX-8064 is a specific and potent antagonist antibody of LILRB2
(leukocyte immunoglobulin like receptor B2; ILT4)
- LILRB2 binds to its ligands (classical MHC I molecules [e.g.
HLA-A, HLA-B] and non-classical MHC I molecules [e.g. HLA-G]) and
maintains an immuno-suppressive state in macrophages. JTX-8064
blocks ligand binding to LILRB2 and induces an immune activating
state in macrophages that may lead to enhancement of the anti-tumor
immune response
- Inhibiting LILRB2 induces pro-inflammatory cytokine secretion
and a unique transcriptional profile suggestive of an M1-like shift
in human macrophages, which is distinct from macrophage-targeted
mAbs CSF1R and TIM-3
The poster is available on the “Our Approach” section of the
Jounce Therapeutics website at www.jouncetx.com.
About JTX-8064JTX-8064 is an anti-Leukocyte
Immunoglobulin Like Receptor B2 (LILRB2) antibody and is the first
candidate to emerge from Jounce’s Translational Science Platform
efforts that focuses on tumor-associated macrophages. Preclinical
data presented at the 2019 AACR Annual Meeting supports the
development of JTX-8064 as a novel immunotherapy to reprogram
immune-suppressive macrophages and enhance anti-tumor immunity.
JTX-8064 is currently in IND-enabling activities and Jounce
anticipates filing an IND and initiating a Phase 1 clinical trial
for JTX-8064 in 2019.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three
development-stage programs: its two clinical product candidates,
vopratelimab, a monoclonal antibody that binds to and activates
ICOS, and JTX-4014, a monoclonal antibody that binds to PD-1 and
for potential use in combination with Jounce’s pipeline of future
product candidates, and JTX-8064, a monoclonal antibody that binds
to LILRB2 that is currently in the IND-enabling phase. For more
information, please visit www.jouncetx.com.
Forward-Looking StatementsStatements in this
release concerning Jounce’s future expectations and plans,
including without limitation, Jounce’s expectations regarding the
timing of filing of an Investigational New Drug application and
initiation of a Phase 1 clinical trial of JTX-8064, and Jounce’s
clinical development strategy may constitute forward looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws and are subject to substantial risks, uncertainties
and assumptions. You should not place reliance on these forward
looking statements, which include words such as “believe,”
“expect,” “aims,” “anticipates,” “intend,” “may,” “potential” or
similar terms, variations of such terms or the negative of those
terms. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the
Company cannot guarantee such outcomes. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as those risks
more fully discussed in the section entitled “Risk Factors” in
Jounce’s most recent annual report on Form 10-K or quarterly report
on Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in Jounce’s subsequent
filings with the U.S. Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Gina NugentThe Yates Network(617)
460-3579gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024